

PROVINCIAL FUNDING SUMMARY

Fulvestrant (Faslodex) for Locally Advanced or Metastatic Breast Cancer (pCODR 10110)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: February 16, 2018

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Negotiations were closed as an agreement could not be reached		
AB	Funded		Monotherapy in the treatment of postmenopausal women with non-visceral locally advanced or metastatic HER2-negative breast cancer, regardless of age, who have not been previously treatment with endocrine therapy (including in the adjuvant setting) and who have a good performance status. Treatment should continue until unacceptable toxicity or disease progression. Not to be used after Palbociclib and aromatase inhibitor.
SK	Negotiations were closed as an agreement could not be reached		
MB	Negotiations were closed as an agreement could not be reached		
ON	Negotiations were closed as an agreement could not be reached		
NS	Negotiations were closed as an agreement could not be reached		

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NB	Negotiations were closed as an agreement could not be reached		
NL	Funded	Oct 22, 2019	<p>For the treatment of postmenopausal women with non-visceral locally advanced or metastatic estrogen receptor positive, HER2 negative breast cancer, who have not been previously treated with endocrine therapy.</p> <p>Renewal Criteria:</p> <ul style="list-style-type: none"> •Written confirmation that the patient is responding to treatment. <p>Clinical Note:</p> <ol style="list-style-type: none"> 1. Patients must have a good performance status 2. Coverage will not be considered in combination with CDK4/6 inhibitors 3. Treatment should be discontinued upon clinically meaningful disease progression or unacceptable toxicity. <p>Claim Notes:</p> <ul style="list-style-type: none"> •Initial approval period: 1 year. •Renewal approval period: 1 year
PEI	Negotiations were closed as an agreement could not be reached		